Loading
Almost every alpha cancer therapy in development relies on one scarce isotope. Developing several alternatives at once would stop the whole field waiting on a single supply chain.
Actinium-225 dominates targeted alpha therapy pipelines, but lead-212 (from thorium-228/radium-224 generators, used by Orano Med and Perspective Therapeutics), astatine-211 (cyclotron-produced, short half-life, suited to regional supply) and terbium-149 have complementary properties and independent supply routes. The proposal is a public-private programme that funds isotope-agnostic chelator and linker chemistry, comparative dosimetry and small head-to-head clinical studies so that a given targeting ligand can be paired with whichever alpha emitter is available, and that de-risks generator and cyclotron capacity for each.
Shares Alpha vs beta emitters, Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy, Targeted alpha therapy, Manufacturing cost and time for living and radioactive medicines.
Shares Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy, Targeted alpha therapy, Manufacturing cost and time for living and radioactive medicines.
Shares Perspective Therapeutics, Alpha vs beta emitters, Targeted alpha therapy.
Shares Orano Med, Targeted alpha therapy, Manufacturing cost and time for living and radioactive medicines.
Shares Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy, Manufacturing cost and time for living and radioactive medicines.
Shares Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy, Manufacturing cost and time for living and radioactive medicines.
Shares Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy, Manufacturing cost and time for living and radioactive medicines.
Shares Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy, Manufacturing cost and time for living and radioactive medicines.